News stories about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.2168968103565 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
SBPH has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Spring Bank Pharmaceuticals in a research note on Wednesday, July 19th. They set an “overweight” rating and a $29.00 price objective on the stock. Chardan Capital reduced their price objective on shares of Spring Bank Pharmaceuticals from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, August 1st. ValuEngine downgraded shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $26.33.
In related news, Director David Arkowitz purchased 2,500 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average cost of $12.24 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the director now directly owns 17,086 shares in the company, valued at approximately $209,132.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have bought 5,500 shares of company stock worth $70,160. Company insiders own 17.60% of the company’s stock.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.